Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer

@article{Moul2009TwentyYO,
  title={Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer},
  author={Judd W. Moul},
  journal={Cancer},
  year={2009},
  volume={115}
}
  • J. Moul
  • Published 2009
  • Medicine
  • Cancer
fessional career has been marked by ‘‘the CAB debate.’’ Although I suspect that academic debate surrounds most common and uncommon diseases in medicine, debates around the diagnosis, staging, and management of prostate cancer seem to be more controversial, intense, and long-lasting. Those in and outside of the field attribute this to the lack of randomized controlled trials (RCTs) addressing many of the important issues. Although this may be true for many prostate debates, it is not true for… Expand
Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
TLDR
This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. Expand
Proven Efficacy of Combined Androgen Depletion Therapy
  • H. Akaza
  • Medicine
  • Current urology reports
  • 2010
TLDR
A multicenter, double-blind, controlled trial directly compared CAB with bicalutamide, 80 mg, (the 80 mg dose is licensed for CAB and monotherapy in Japan) versus castration alone and instigated the Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer to conduct a long-term follow-up of patients who were enrolled in the original study and were still alive after the trial completed. Expand
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
TLDR
A summary of the 2010 version of the EAU guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC) summarise the most recent findings and put them into clinical practice. Expand
EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
TLDR
The 2013 EAU guidelines on PCa summarise the most recent findings and put them into clinical practice, and suggest follow-up after ADT should include analysis of PSA and testosterone levels, and screening for cardiovascular disease and metabolic syndrome. Expand
MDV3100 for the treatment of prostate cancer
TLDR
Full analysis of safety and efficacy data is awaited; however, MDV3100 appears to be a well-tolerated addition to the expanding portfolio of effective drugs for the treatment of advanced prostate cancer. Expand
Cardiovascular toxicities of systemic treatments of prostate cancer
TLDR
Clinical trial methodology could be improved by the enrolment of greater numbers of patients >65 years of age, and the use of comprehensive cardiological evaluations, and closer collaboration between oncologists and cardiologists is essential for the identification and/or management of cardiovascular adverse events in patients with prostate cancer. Expand
Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade
TLDR
Second-line MAB using an alternative antiandrogen is an effective treatment option before cytotoxic chemotherapy in patients who relapse after initial MAB. Expand
Hormonal therapy for prostate cancer: Current topics and future perspectives
TLDR
The present reviews are focused on these treatment modalities as current topics and perspectives of hormone therapy for prostate cancer, such as intermittent androgen suppression, non-steroidal anti-androgen monotherapy, alternative antiandrogen therapy for initial MAB/CAB relapsed cases and deferred MAB-CAB have been developed. Expand
EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer - Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración
TLDR
A summary of the 2010 version of the European Association of Urology guidelines on the treatment of advanced, relapsing, and castration-resistant prostate cancer (CRPC) summarise the most recent findings and put them into clinical practice. Expand
Guidelines on Prostate Cancer
TLDR
The introduction of an effective blood test, prostate specific antigen (PSA), has made it possible to diagnose more and more men in an earlier stage where they can be offered potentially curative treatments, and this is the subject of the EAU guidelines on prostate cancer. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 14 REFERENCES
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials
TLDR
In advanced prostate cancer, addition of an antiandrogen to AS improved the 5-year survival by about 2% or 3% (depending on whether the analysis includes or excludes the cyproterone acetate trials), but the range of uncertainty as to the true size of this benefit runs from about 0% to about 5%. Expand
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma.
TLDR
Treatment with le uprolide and flutamide is superior to treatment with leuprolide alone in patients with advanced prostate cancer, and Symptomatic improvement was greatest during the first 12 weeks of the combined androgen blockade. Expand
A re‐assessment of the role of combined androgen blockade for advanced prostate cancer
TLDR
A wide range of other issues are addressed in this section: bilateral testicular cancer, male‐factor infertility, and buccal mucosa urethroplasty, of interest to general urologists, as well as to those with a more specific area of interest. Expand
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
TLDR
ADT is associated with an increased risk of multiple side effects that may reduce quality of life and/or OS, so ADT should be used with knowledge of its potential long-term side effects and with possible lifestyle interventions, especially in settings with the highest risk-benefit ratio. Expand
Combined androgen blockade with bicalutamide for advanced prostate cancer
A previously reported, double‐blind, randomized, multicenter phase 3 trial in 205 patients with stage C/D prostate cancer compared combined androgen blockade (CAB) with luteinizing hormone‐releasingExpand
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
TLDR
Bilateral orchiectomy or luteinizing hormone-releasing hormone agonists are recommended initial androgen-deprivation treatments (ADTs) and data are insufficient to support use of intermittent androgen blockade outside clinical trials. Expand
Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy.
TLDR
The retrospective observational multicenter database analysis demonstrated that early HT administered for PSAR after prior RP was an independent predictor of delayed clinical metastases only for high-risk cases at the current followup. Expand
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
TLDR
Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk of recurrence in patients with node-positive prostate cancer. Expand
Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE.
TLDR
Findings show a reduction in the incidence of metastatic disease at initial prostate cancer diagnosis, and biologic, rather than socioeconomic, factors are associated with this type of disease presentation. Expand
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
TLDR
Study results demonstrate effective anticancer responses during extended exposure to abarelix: improvements in pain score and/or analgesic use, improvements in urinary symptoms, and complete avoidance of bilateral orchiectomy for patients undergoing at least 12 weeks of treatment. Expand
...
1
2
...